Related Experiment Video
Updated: Apr 20, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Abrupt nicotine reduction as an endgame policy: a randomised trial
Natalie Walker1, Trish Fraser2, Colin Howe1
1National Institute for Health Innovation (NIHI), School of Population Health, The University of Auckland, Auckland, New Zealand.
Smokers unmotivated to quit significantly reduced their usual cigarette intake when offered cheaper, very low nicotine content (VLNC) cigarettes. This intervention also lowered tobacco dependence and increased quitting rates.
Area of Science:
- Public Health
- Addiction Medicine
- Nicotine Research
Background:
- Many smokers are unmotivated to quit despite health risks.
- Reducing nicotine content in cigarettes is a potential harm reduction strategy.
- Understanding price sensitivity for reduced nicotine products is crucial.
Purpose of the Study:
- To assess if unmotivated smokers reduce consumption with cheaper very low nicotine content (VLNC) cigarettes.
- To evaluate the impact of VLNC cigarettes on smoking behavior and dependence.
Main Methods:
- A randomized controlled trial involving dependent adult smokers unmotivated to quit.
- Intervention group received free VLNC cigarettes; control group purchased usual brands.
- Primary outcome: change in daily cigarette consumption at 12 weeks.
Main Results:
- A NZ$15 price difference for VLNC cigarettes halved daily consumption.
- Tobacco dependence decreased, and quitting increased in the intervention group.
- Total cigarette consumption (usual + VLNC) was similar, but nicotine exposure was reduced.
Conclusions:
- Reduced pricing of VLNC cigarettes effectively lowers consumption and nicotine exposure in unmotivated smokers.
- This strategy shows promise for harm reduction among populations resistant to quitting.
- Price incentives are key to encouraging reduced nicotine product adoption.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
CNS Depressants: Alcohol and Nicotine
Phase I Reactions: Reductive Reactions
Drug Dependence

